Vitality Biopharma Seeks FDA’s Orphan Drug Status for Cannabinoid Therapy VITA-100

Vitality Biopharma Seeks FDA’s Orphan Drug Status for Cannabinoid Therapy VITA-100
Vitality Biopharma is seeking orphan drug designation from the U.S. Food and Drug Administration (FDA) for its targeted cannabinoid therapy, VITA-100, for the treatment of pediatric ulcerative colitis. The FDA grants orphan drug status to promising treatments for rare diseases affecting fewer than 200,000 people per year in the United States. Upon approval, the designation is expected

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *